Zenith Drugs

Why is Zenith Drugs Ltd falling/rising?

As of 23-Jun, Zenith Drugs Ltd's stock price is at 42.50, down 2.07% today, despite recent gains over the past week and month. The stock's performance is hindered by underperformance relative to its sector, a year-to-date decline of 15.34%, and mixed moving average indicators, although increased investor participation is noted.

As of 23-Jun, Zenith Drugs Ltd's stock price is currently at 42.50, reflecting a decrease of 0.9, or 2.07%. This decline can be attributed to several factors. Despite a positive performance over the past week and month, where the stock rose by 3.41% and 9.11% respectively, it has significantly underperformed today, lagging behind its sector by 2.82%. <BR><BR>Additionally, while the stock is trading above its 5-day and 50-day moving averages, it remains below the 20-day, 100-day, and 200-day moving averages, indicating a potential downward trend in the short to medium term. Furthermore, the stock has experienced a year-to-date decline of 15.34%, which is more pronounced than the benchmark Sensex's decline of 8.82%. <BR><BR>On a positive note, there has been a notable increase in investor participation, with delivery volume rising by 200% against the 5-day average. However, the overall liquidity remains stable, suggesting that while there is some interest, it has not translated into upward price momentum. Thus, the combination of underperformance today, relative moving averages, and significant year-to-date losses contributes to the current decline in Zenith Drugs Ltd's stock price.

Which are the latest news on Zenith Drugs?

What does Zenith Drugs do?

Zenith Drugs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently converted to a Public Limited Company. It has a market cap of INR 75 Cr, with key metrics including a P/E ratio of 19.00 and a debt-equity ratio of 0.72.

Overview: <BR>Zenith Drugs Ltd is a company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History: <BR>Zenith Drugs Limited was originally incorporated on November 15, 2000, as "Zenith Drugs Private Limited." It was later converted into a Public Limited Company, with the name changed to "Zenith Drugs Limited" following the issuance of a Fresh Certificate of Incorporation on September 13, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 75 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 19.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.72 <BR>Return on Equity: 5.49% <BR>Price to Book: 1.03 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Zenith Drugs?

As of 10th June, Zenith Drugs Ltd has a market capitalization of 75.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 62.26 Cr and Total Assets of 134.97 Cr; however, there is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Zenith Drugs Ltd has a market capitalization of 75.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 62.26 Cr and Total Assets valued at 134.97 Cr.

Who are the peers of the Zenith Drugs?

Zenith Drugs' peers include Vilin Bio Med, Onyx Biotec, Ajooni Biotech, JFL Life, Vineet Laborator, Phaarmasia, Bacil Pharma, Source Natural, and Bharat Immunolog. Zenith Drugs has the lowest 1-year return at -36.50%, while Vilin Bio Med leads with 75.50%.

Peers: The peers of Zenith Drugs are Vilin Bio Med, Onyx Biotec, Ajooni Biotech, JFL Life, Vineet Laborator, Phaarmasia, Bacil Pharma, Source Natural, Bharat Immunolog.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vilin Bio Med, Zenith Drugs, Vineet Laborator, Phaarmasia, and Bharat Immunolog, while Average management risk is found at Onyx Biotec and JFL Life. Ajooni Biotech exhibits Good capital structure, while JFL Life and Source Natural also show Good capital structure. Average growth is seen at Onyx Biotec, Phaarmasia, and the rest, while Excellent growth is noted at JFL Life.<BR><BR>Return Snapshot: Vilin Bio Med has the highest 1-year return at 75.50%, while Zenith Drugs has the lowest at -36.50%. Zenith Drugs' 1-year return is significantly lower than its peers. Additionally, JFL Life, Ajooni Biotech, and Zenith Drugs have negative six-month returns.

Is Zenith Drugs overvalued or undervalued?

As of November 18, 2025, Zenith Drugs is considered overvalued at a price of 57.35, with a PE ratio of 13.74 and a significant underperformance of -39.05% compared to the Sensex, especially when compared to its peers like Sun Pharma and Divi's Lab, which have much higher PE ratios.

As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued.

How has been the historical performance of Zenith Drugs?

Zenith Drugs has shown significant growth over the past three years, with net sales increasing from 91.66 Cr in March 2022 to 131.62 Cr in March 2024, and operating profit rising from 7.85 Cr to 19.03 Cr. Despite negative cash flow from operations, the company has expanded its asset base and achieved strong profitability improvements.

Answer:<BR>The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, from 68.58 Cr in March 2022 to 134.97 Cr in March 2024, reflecting a robust expansion strategy. Cash flow from operating activities has been negative in recent years, but cash flow from investing activities turned positive in March 2024, contributing to a net cash inflow of 8.00 Cr. Overall, Zenith Drugs has demonstrated strong growth in sales and profitability, alongside an expanding asset base, despite challenges in cash flow from operations.

Who are the top shareholders of the Zenith Drugs?

The top shareholders of Zenith Drugs include promoter Ajay Singh Dassundi with 22.52%, individual investors with 25.56%, and public shareholder Praveen Mudunuri at 1.21%. There are also two foreign institutional investors holding 0.06%, and no mutual funds are currently invested in the company.

The top shareholders of Zenith Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Singh Dassundi, owning 22.52% of the company. Additionally, individual investors collectively hold 25.56% of the shares. In terms of institutional investors, there are two foreign institutional investors (FIIs) that hold a small portion, specifically 0.06%. The highest public shareholder is Praveen Mudunuri, with a holding of 1.21%. There are no mutual funds currently holding shares in the company.

What is the technical trend for Zenith?

As of May 30, 2025, Zenith's technical trend has shifted to mildly bearish, supported by bearish signals from the MACD, moving averages, and Dow Theory, despite a conflicting bullish KST signal.

As of 30 May 2025, the technical trend for Zenith has changed from sideways to mildly bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly time frames. Although the KST shows a bullish signal on the weekly, the overall sentiment is dampened by the bearish signals from the Bollinger Bands and the OBV, which is mildly bearish on the weekly but bullish on the monthly. The stock has underperformed significantly against the Sensex over the past month and year-to-date, further reinforcing the bearish sentiment.

When is the next results date for Zenith?

No Upcoming Board Meetings

Has Zenith declared dividend?

Zenith Drugs Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 17, 2024. While the dividend yield is 0.73%, total returns have varied significantly, showing a -22.92% return over the last 6 months and a modest 9.75% return over the past year.

Zenith Drugs Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.73%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.92%, the dividend return was 0%, resulting in a total return of -22.92%.<BR><BR>Over the past year, the price return was 8.98%, the dividend return was 0.77%, leading to a total return of 9.75%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 5-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Zenith has declared a dividend, the total returns over various periods show mixed results, with significant negative returns in the short term and modest positive returns in the longer term. The dividend yield is relatively low, indicating that while dividends are being paid, the overall performance may not be strong.